UPDATE: Needham On Accolade Price Target Cut: Firm Warns On 'Recent Broad-Based Multiple Compression Across Digital Health Space'; Highlights Solid Q2 Results Given 32% Proforma Y/Y Growth & Expects Sustainable 30% Growth & Margin Expansion Going Foward